AN2 Therapeutics, Inc.
ANTX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ANTX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ANTX
AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel therapies for infectious diseases, with a lead candidate epetraborole targeting Mycobacterium abscessus and a drug discovery platform for other indications.
Key risk: No approved products or revenue
BioSniper Score
Based on 6 of 6 signals
Market Cap
$210.6M
Cash Runway
33.1 moLead Asset
an2-502998 (Phase 1)
Next Catalyst
Phase2_Topline · Dec 31, 2027Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 2 clinical trials · 1 catalyst for AN2 Therapeutics, Inc..
AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel therapies for infectious diseases, with a lead candidate epetraborole targeting Mycobacterium abscessus and a drug discovery platform for other indications.
- Lead product candidate epetraborole is in Phase 2/3 clinical development for Mycobacterium abscessus lung disease [sec_mda · as of 2026-08-11].
- Cash, cash equivalents, and investments of $44.3 million as of June 30, 2026, expected to fund operations for at least the next 12 months [sec_mda · as of 2026-08-11].
- Net loss of $8.2 million for the quarter ended June 30, 2026 [latest reported financials].
- Company has not yet demonstrated ability to complete pivotal trials, obtain regulatory approvals, or commercialize a product [sec_mda · as of 2026-08-11].
- Pipeline is primarily early- to mid-stage, with no clinical proof of concept established for any product candidate [sec_mda · as of 2026-08-11].
What works
- Cash runway of at least 12 months provides near-term operational stability [sec_mda · as of 2026-08-11].
- Epetraborole targets a significant unmet need in Mycobacterium abscessus lung disease, a rare and difficult-to-treat infection [sec_mda · as of 2026-08-11].
- Company has raised substantial capital through multiple offerings, including $40 million in March 2026, indicating ongoing investor support [sec_mda · as of 2026-05-11].
What to weigh
- No product candidate has achieved clinical proof of concept or regulatory approval, making future success highly uncertain [sec_mda · as of 2026-08-11].
- Company expects negative cash flows to increase significantly as it advances candidates through clinical development [sec_mda · as of 2026-05-11].
- Substantial additional funding will be needed beyond the current cash runway to continue operations and planned activities [sec_mda · as of 2026-08-11].
- Early-stage drug development carries inherent risks of translation from preclinical to human studies, which may prevent achieving meaningful clinical results [sec_mda · as of 2026-08-11].
From the filings
Quoted directly from source documents.
Cash runway of at least 12 months
“existing cash, cash equivalents, and investments will enable us to fund our operating expenses and capital expenditure requirements for at least the next 12 months.”
SEC MD&A · August 11, 2026
No clinical proof of concept established
“clinical proof of concept has not yet been established for any of our product candidates.”
SEC MD&A · August 11, 2026
Need for substantial additional funding
“we will need to obtain substantial additional funding in connection with our continuing operations and planned activities.”
SEC MD&A · August 11, 2026
Company has not demonstrated ability to commercialize
“we have not yet demonstrated an ability to successfully complete pivotal clinical trials, obtain regulatory approvals, manufacture a commercial product or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful commercialization.”
SEC MD&A · August 11, 2026
Catalyst timeline
- 2027-12-31 · Phase2_Topline · leucyl-trna synthetase — Phase 2 Readout: leucyl-trna synthetase — Topline data from the Phase 2 trial of epetraborole (leucyl-tRNA synthetase inhibitor) in Mycobacterium abscessus lung disease will be a key efficacy and safety readout.
Risks & what to watch (4)›
Key risks
- No approved products or revenue — Company has no products approved for commercial sale and has not generated any revenue from product sales [sec_mda · as of 2026-08-11].
- Clinical development uncertainty — Epetraborole and other candidates are in early- to mid-stage trials; failure to demonstrate safety/efficacy could halt programs [sec_mda · as of 2026-08-11].
- Need for additional capital — Current cash may not be sufficient to complete all planned development; future fundraising may be dilutive or unavailable [sec_mda · as of 2026-08-11].
- Regulatory and manufacturing risks — Company has no experience in regulatory approval or commercial manufacturing, which could delay or prevent product launch [sec_mda · as of 2026-08-11].
What to watch
- Phase 2 topline data for epetraborole in Mycobacterium abscessus lung disease, expected by end of 2027 [upcoming catalysts].
- Cash burn rate and any additional financing activities, as the company will need substantial funding beyond current runway [sec_mda · as of 2026-08-11].
- Progress of preclinical and early-stage pipeline programs, which are key to long-term value but carry high uncertainty [sec_mda · as of 2026-08-11].
- Regulatory interactions and IND filings for new candidates, which could impact development timelines [sec_mda · as of 2026-08-11].
Sources: SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run AN2 Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available AN2 Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
33.1 months
D/E 0.08 · 0% dilution
Lead: Phase 2/Phase 3
2 candidates
1 upcoming, next in ~488d
0 buys · 5 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
46
Total value held
$48.3M
| Holder | Shares | Value |
|---|---|---|
| commodore capital lp | 2,333,713 | $8.0M |
| millennium management llc | 2,222,502 | $7.6M |
| vanguard capital management llc | 2,022,156 | $6.9M |
| adage capital partners gp, l.l.c. | 1,000,000 | $3.4M |
| ameriprise financial inc | 696,181 | $2.4M |
| sio capital management, llc | 657,200 | $2.2M |
| ally bridge group (ny) llc | 526,315 | $1.8M |
| prosight management, lp | 515,754 | $1.8M |
| bank of nova scotia | 459,194 | $1.6M |
| bank of america corp /de/ | 393,702 | $1.3M |
Showing top 10 of 46 institutional holders of AN2 Therapeutics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 2.9%
- Days to cover
- 2.6
- Shares short
- 879,488
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ANTX short interestGovernance
Frequently asked questions
What is the AI investment thesis for AN2 Therapeutics, Inc.?
AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel therapies for infectious diseases, with a lead candidate epetraborole targeting Mycobacterium abscessus and a drug discovery platform for other indications.
What is AN2 Therapeutics, Inc.'s lead drug candidate?
AN2 Therapeutics, Inc.'s most advanced tracked candidate is an2-502998 (Phase 1) for Chagas disease.
What is AN2 Therapeutics, Inc.'s next catalyst?
AN2 Therapeutics, Inc.'s next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: leucyl-trna synthetase" — expected December 31, 2027.
Who is the CEO of AN2 Therapeutics, Inc.?
Mr. Eric E. Easom is the chief executive officer of AN2 Therapeutics, Inc. (ANTX).
Where is AN2 Therapeutics, Inc. headquartered?
AN2 Therapeutics, Inc. (ANTX) is headquartered in Menlo Park, CA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.